Prostate cancer can be targeted by ligands to the prostate-specific membrane antigen (PSMA). We aimed to evaluate dosimetry, safety and efficacy of 177Lu-PSMA-617 radioligand therapy (RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC).Fifteen patients each received two cycles of 3.7 GBq (n = 5) or 6.0 GBq (n = 10) 177Lu-PSMA-617 at an eight to ten weeks interval. For ...

RIT has become an attractive strategy in cancer treatment, but still faces important drawbacks due to poor tumor penetration and undesirable pharmacokinetics of the targeting vehicles. Smaller radiolabeled antibody fragments and peptides feature highly specific target accumulation, resulting in low accumulation in healthy tissue, except for the kidneys. Nanobodies are the smallest (MW<15 kDa) f...

A patient with anaplastic meningioma and lung metastases resistant to conventional treatment underwent radiopeptide therapy with 177Lu- DOTA-octreotate in our institute. The treatment resulted in significant improvement in patient's quality of life and inhibition of tumor progression. This case may eventually help to establish the value of radiopeptide therapy in patients with this rare condition.

Background The aim of this study was to evaluate the palliative efficacy of localized external radiotherapy (RT) combined with systemic radionuclide (RN) therapy in patients who had multiple painful osseous metastases of different primary origins. Methods Thirty-three patients initially local external radiotherapy was delivered to the most symptomatic region in all patients. Then they receive...

Designing ideal radiopharmaceuticals for use as bone pain palliatives require the use of a moderate energy β emitter with a stable carrier molecule. Cyclic polyaminophosphonate ligands are known to form complexes with higher thermodynamic stability and kinetic inertness. The present study therefore envisages the use of a few moderate energy β emitters, viz. Lu (T1/2 = 6.71 d, Eβmax= 497 keV), S...

Amaç: Son yıllarda, hedefe yönelik radyonüklid tedavisindeki ilerlemeler sayesinde hastalıkların erken teşhis ve tedavisinde önemli gelişmeler kaydedilmiştir. Tanı tedavi yöntemlerini birleştiren “teranostik” kavramının doğmasıyla Lutesyum-177 (Lu-177), tedavide bir yer edinmiş bu alanda öncü bileşik haline gelmiştir. Bu derlemede, radyofarmasötikler, tedavi, teranostikler Lu-177 ile ilgili tem...

In molecular radiotherapy with 177Lu-labeled prostate specific membrane antigen (PSMA) peptides, kidney and/or salivary glands doses limit the activity which can be administered. The aim of this work was to investigate the effect of the ligand amount and injected activity on the tumor-to-normal tissue biologically effective dose (BED) ratio for 177Lu-labeled PSMA peptides. For this retrospectiv...

BACKGROUND Dosimetry in radionuclide therapy has the potential to allow for a treatment tailored to the individual patient. One therapeutic radiopharmaceutical where patient-specific dosimetry is feasible is 177Lu-DOTATATE, used for the treatment of neuroendocrine tumours. The emission of gamma photons by 177Lu allows for imaging with SPECT (single photon emission computed tomography). One impo...

The pretargeting system based on the inverse electron demand Diels-Alder reaction (IEDDA) between trans-cyclooctene (TCO) and tetrazine (Tz) combines the favorable pharmacokinetic properties of radiolabeled small molecules with the affinity and specificity of antibodies. This strategy has proven to be an efficient method for the molecularly targeted delivery of pharmaceuticals, including isotop...